Bioatla
Bioatla is a biotechnology company specializing in the discovery and development of conditionally active biologics for oncology and other therapeutic areas. Utilizing its proprietary CAB (Conditionally Active Biologics) technology platform, Bioatla engineers monoclonal antibodies and antibody-drug conjugates designed to selectively target cancer cells while minimizing impact on healthy tissue. The company’s innovative approach aims to improve the efficacy and safety profile of immunotherapies, addressing unmet medical needs in cancer treatment. Bioatla collaborates with industry partners to advance its pipeline of differentiated biologic therapies, leveraging scientific expertise and advanced research capabilities. Committed to transforming patient outcomes, Bioatla continues to drive innovation in the field of targeted biologic therapeutics.
